Patient P-03090

Synthetic patientONX-7 · Day 147 · 55–64 · F · baseline S02Open companion preview

Therapy response

Stable

Tolerance

Favorable

GI state

Deteriorating

Inflammatory state

Stable

Nutritional resilience

Declining

Discontinuation risk

68%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S02
Day 62 GI-04 recommended — GI Support Protocol GI-04
Day 63 Patient accepted — Started GI-04 in the companion
Day 71 GI symptom burden −40% vs expected — GI Support Protocol GI-04
Day 75 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 75 ME-01 recommended — Monitoring Escalation ME-01
Day 76 Patient accepted — Started ME-01 in the companion
Day 77 Tolerance state changed — Unstable → Improving
Day 79 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 75.

Primary contributors, last 14 days

Nutritional resilience-15
GI instability+12
Treatment adherence+8

What helped?

GI Support Protocol GI-04Day 62
Result: symptom burden −40%
Monitoring Escalation ME-01Day 75
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

60%

probability of meaningful tolerance improvement

284 similar trajectories
73% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 47
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 28/100
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓20
- Wearable3,504 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 28/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 46 ms
Sleep: 6.8 h
Steps: 3,732
Resting HR: 69 bpm

Daily log: GI score 53, nutritional resilience 43, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03070	53%	S14	GI-04	improved	51
P-03300	51%	S14	GI-04	improved	46
P-03123	47%	S14	GI-04	improved	50
P-03145	47%	S14	GI-04	improved	51
P-03146	46%	S14	GI-04	improved	53
P-03110	45%	S15	GI-04	improved	52
P-03226	45%	S05	GI-04	improved	43
P-03159	44%	S14	GI-04	improved	37
P-03430	44%	S14	SC-12	improved	45
P-03323	42%	S14	GI-04	improved	48
P-03049	41%	S14	GI-04	improved	49
P-03037	40%	S14	NP-02	improved	43